Related Experiment Video
Updated: Jun 11, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Tocilizumab for rheumatoid arthritis.
Jasvinder A Singh1, Saba Beg, Maria Angeles Lopez-Olivo
1Department of Medicine, Birmingham VA Medical Center, Faculty Office Tower 805B, 510 20th Street South, Birmingham, USA, AL 35294.
The Cochrane Database of Systematic Reviews
|July 9, 2010
Summary
Tocilizumab effectively reduces rheumatoid arthritis (RA) disease activity and improves function. However, it is associated with increased adverse events and cholesterol levels, necessitating further safety research.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Tocilizumab is an interleukin-6 inhibitor approved for rheumatoid arthritis (RA) treatment.
- This systematic review evaluates tocilizumab's efficacy and safety in RA patients.
Purpose of the Study:
- To assess the efficacy and safety of tocilizumab in RA patients.
- Utilizing data from published randomized or quasi-randomized controlled trials (RCTs).
Main Methods:
- Systematic review of eight RCTs involving 3334 participants.
- Data extraction included efficacy (ACR50, DAS remission, HAQ/mHAQ) and safety outcomes.
- Risk ratios and mean differences were calculated for dichotomous and continuous outcomes, respectively.
Main Results:
- Tocilizumab significantly improved ACR50, DAS remission, and HAQ/mHAQ scores compared to placebo in RA patients on methotrexate.
- Patients receiving tocilizumab showed a higher incidence of adverse events but were less likely to withdraw from therapy.
- Elevated cholesterol and triglyceride levels were observed in tocilizumab-treated patients; no significant differences in serious adverse events or withdrawals due to adverse events were noted.
Conclusions:
- Tocilizumab demonstrates significant benefits in reducing RA disease activity and enhancing patient function.
- Treatment with tocilizumab is linked to increased adverse events and lipid levels.
- Further large-scale safety studies are required to fully address the safety profile of tocilizumab in RA management.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms: